A first-in-human study of the novel immunology antibody drug conjugate, ABBV-3373, in healthy participants.

ABBV-3373 had favorable PK profiles, manageable immunogenicity, and was generally well tolerated. Except for a transient effect at 900 mg IV, there was no apparent impact on serum cortisol. Study results supported further clinical development of ABBV-3373.